Viking Therapeutics VKTX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's investing cash flow?
- Viking Therapeutics (VKTX) reported investing cash flow of $54.19M in Q1 2026.
- How has Viking Therapeutics's investing cash flow changed year-over-year?
- Viking Therapeutics's investing cash flow decreased by 14.3% year-over-year, from $63.25M to $54.19M.
- What is the long-term trend for Viking Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Viking Therapeutics's investing cash flow has grown at a 199.9% compound annual growth rate (CAGR), from $37.96M to $341.39M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.